Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises of AL102, a gamma secretase inhibitor which is in phase 3 clinical trial for the treatment of desmoid tumors; IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates which is in phase 1 clinical trial; and preclinical asset consist of IM-3050, a fibroblast activation protein targeted radioligand therapy. It also develops solid tumor ADC drug candidates which includes IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Immunome Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunome (IMNM) and COMPASS Pathways (CMPS) with bul...

Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), COMPASS Pathways (CMPS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alkermes (ALKS) and Immunome (IMNM) with bullish sen...

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Immunome (IMNM)

Immunome, Inc. ($IMNM) announced an update on their ongoing clinical study. Immunome, Inc. is running an early clinical trial called “A Phase 1 Stu...

Immunome’s New Radiopharma Trial Puts IMNM on Early Oncology Watchlists

Immunome ( ($IMNM) ) has issued an update. Immunome, Inc. held its 2026 Annual Meeting of Stockholders on June 9, 2026, with 113,249,519 common sha...

Immunome shareholders reaffirm board, auditor and pay policies

Wedbush analyst maintained a Buy rating on Immunome today and set a price target of $31.00. Immunome has an analyst consensus of Strong Buy, with a...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IMNM	$23.35	-3.39%	1.11M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IMNM	$23.35	-3.4%	1.11M
3
4
5
6

IMNM

IMNM

Get Immunome Inc. Data in Excel

Get Immunome Inc. Data in Excel